Major Progress! First Patient Successfully Enrolled in Nanolattix T320 Clinical Trial
Release time:
2025-07-09
Nanolattix’s self-developed antibody-drug conjugate (ADC) T320-ADC has achieved a significant breakthrough! The project progressed rapidly under the efficient coordination of the Chinese Academy of Medical Sciences Cancer Hospital as the leading unit. Guided by the expert team led by Professor Li Ning, the clinical trial initiation meeting was successfully held in Beijing on May 27, 2025. The project team demonstrated exceptional execution efficiency—just 72 hours after the meeting (May 30), the first subject’s informed consent was completed, and on June 10, the first patient was successfully dosed, marking the first-in-human administration of this ADC product. This fully reflects the "Nanolattix Speed" and lays a solid foundation for the smooth progression of subsequent clinical trials.
T320 is a TF-targeting ADC with a structure and payload similar to TIVDAK®. It specifically binds to TF on the surface of tumor cells. As a structurally optimized ADC, T320 has demonstrated significant anti-tumor activity in multiple tumor xenograft models, with superior efficacy to TIVDAK while exhibiting lower side effects at equivalent doses and better safety. These characteristics make it a promising new option in the field of TF-targeted therapy.
Currently, Nanolattix is conducting a Phase I clinical trial (National Drug Clinical Trial Registration No.: CTR20251284) across China, with the Chinese Academy of Medical Sciences Cancer Hospital as the leading unit, to evaluate T320 in advanced solid tumors. The trial is actively recruiting participants. This study provides free access to cutting-edge ADC-targeted therapy for patients with recurrent/metastatic solid tumors (including pancreatic, cervical, ovarian, endometrial, head and neck, and lung cancers) who have progressed after standard treatment. Eligible patients will have the opportunity to:
Receive free treatment with the innovative targeted drug T320
Obtain comprehensive care and diagnosis from a top-tier oncology medical team in Chin
Tag:
recommend News
Share
